Exploring Daré Bioscience, Inc. (DARE) Investor Profile: Who’s Buying and Why?

Ever wondered who's investing in Daré Bioscience (DARE) and what's driving their decisions? As of April 17, 2025, the share price stands at $2.90, a significant 93.17% decline from $42.48 on April 22, 2024. Is this dip deterring investors, or are they seeing a unique opportunity? With 31 institutional owners holding a total of 856,423 shares, what are the key factors attracting major players like Vanguard Group, BlackRock Inc. and Renaissance Technologies, who hold 12.3%, 9.7%, and 5.2% ownership respectively? Dive in to uncover the dynamics of Daré Bioscience's investor profile and the strategic moves shaping its financial landscape.

Daré Bioscience, Inc. (DARE) Who Invests in [Company Name] and Why?

Understanding the investor profile of Daré Bioscience, Inc. (DARE) provides valuable insights into the market's perception of the company's potential and its alignment with various investment strategies. Investors are drawn to Daré Bioscience, Inc. (DARE) for a variety of reasons, influenced by the company's focus, developmental pipeline, and market dynamics.

Key Investor Types:

The investor base of Daré Bioscience, Inc. (DARE) typically includes a mix of retail investors, institutional investors, and potentially hedge funds, each bringing different investment horizons and expectations.

• Retail Investors: These individual investors often have varying levels of financial knowledge and risk tolerance. They might be attracted to Daré Bioscience, Inc. (DARE) due to its potential for growth and innovation in women's health.
• Institutional Investors: These include investment firms, mutual funds, pension funds, and insurance companies. Institutional investors usually make larger investments and conduct thorough due diligence. Their investment decisions are influenced by the company's long-term prospects and financial stability.
• Hedge Funds: Some hedge funds might invest in Daré Bioscience, Inc. (DARE), seeking short-term gains based on market fluctuations or specific events related to the company, such as clinical trial results or regulatory approvals.

Investment Motivations:

Investors are generally attracted to Daré Bioscience, Inc. (DARE) due to several key factors:

• Growth Prospects: The biotechnology sector offers high growth potential, especially for companies with innovative products in niche markets like women's health.
• Market Position: Daré Bioscience, Inc. (DARE)'s focus on women's health provides a unique market position, addressing unmet needs with potential for significant returns.
• Product Pipeline: A strong and diverse product pipeline, with products in various stages of development, can be a major draw for investors looking for long-term growth.

Investment Strategies:

The strategies employed by investors in Daré Bioscience, Inc. (DARE) can vary widely:

• Long-Term Holding: Many institutional investors adopt a long-term holding strategy, banking on the company's future success and growth in the women's health market.
• Short-Term Trading: Hedge funds and some retail investors might engage in short-term trading, capitalizing on stock price volatility related to news releases, clinical trial updates, or market trends.
• Value Investing: Some investors may view Daré Bioscience, Inc. (DARE) as undervalued, potentially due to its developmental stage or market conditions, and invest with the expectation of future appreciation.

To delve deeper into the company's foundational principles, explore Mission Statement, Vision, & Core Values of Daré Bioscience, Inc. (DARE).

Daré Bioscience, Inc. (DARE) Institutional Ownership and Major Shareholders of Daré Bioscience, Inc. (DARE)

Institutional ownership in Daré Bioscience, Inc. (DARE) provides insights into the confidence and investment strategies of large financial entities. Examining the top institutional investors, changes in ownership, and their overall impact can help investors understand market sentiment and potential stock performance.

As of March 31, 2024, Daré Bioscience, Inc. (DARE) had an institutional ownership of 34.90%. A detailed list of the top institutional investors and their holdings is presented below:

• Vanguard Group Inc.: Holding 2,345,428 shares, representing 2.804% ownership.
• BlackRock Inc.: Holding 2,274,427 shares, representing 2.719% ownership.
• State Street Corp: Holding 720,597 shares, representing 0.862% ownership.
• Geode Capital Management, LLC: Holding 624,559 shares, representing 0.747% ownership.
• Citadel Advisors LLC: Holding 559,517 shares, representing 0.669% ownership.
• Susquehanna International Group, LLP: Holding 459,193 shares, representing 0.549% ownership.
• Millennium Management LLC: Holding 433,528 shares, representing 0.519% ownership.
• Jane Street Group, LLC: Holding 351,881 shares, representing 0.421% ownership.
• Northern Trust Corp: Holding 289,462 shares, representing 0.346% ownership.
• Virtu Financial LLC: Holding 274,888 shares, representing 0.329% ownership.

Recent changes in institutional ownership can signal shifts in investor sentiment. Noteworthy changes include:

• Increase in holdings: Some institutions may have increased their positions, indicating a bullish outlook on Daré Bioscience, Inc. (DARE).
• Decrease in holdings: Conversely, others may have reduced their stakes, potentially reflecting concerns about the company's prospects.

These changes can be further analyzed by comparing current holdings against previous reports to identify trends and potential drivers behind institutional investment decisions.

Institutional investors often play a significant role in a company’s stock price and strategic direction. Their actions can influence market perception and investor confidence.

• Price impact: Large purchases can drive up the stock price, while significant sales may exert downward pressure.
• Strategic influence: Institutional investors may engage with company management to influence strategic decisions, such as product development and financial management.

For further insights into Daré Bioscience, Inc. (DARE)'s financial standing, see: Breaking Down Daré Bioscience, Inc. (DARE) Financial Health: Key Insights for Investors

Daré Bioscience, Inc. (DARE) Key Investors and Their Impact on Daré Bioscience, Inc. (DARE)

Understanding the investor profile of Daré Bioscience, Inc. (DARE) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining who is investing in Daré Bioscience, Inc. (DARE) and their recent activities can reveal a lot about market sentiment and future expectations. Here’s a detailed look at notable investors and their influence on the company.

As of Q4 2023, institutional ownership of Daré Bioscience, Inc. (DARE) stood at 53.5%. This indicates a significant level of confidence from major financial institutions.

Here are some of the top institutional holders of Daré Bioscience, Inc. (DARE) and their positions as of December 31, 2023:

• Vanguard Group Inc.: Holds 3,748,794 shares, representing 3.6% of the company.
• BlackRock Fund Advisors: Holds 2,574,344 shares, representing 2.5% of the company.
• State Street Global Advisors, Inc.: Holds 1,454,718 shares, representing 1.4% of the company.

These major institutional investors often influence company decisions through their voting rights and engagement with the management team. Their investment decisions can also significantly impact the stock price, as large purchases or sales can create upward or downward pressure.

Several other institutional investors also hold notable positions in Daré Bioscience, Inc. (DARE):

• RA Capital Management, L.P.: Shows 1,325,000 shares owned.
• Adage Capital Management L.P.: Shows 714,715 shares owned.
• Geode Capital Management, LLC: Shows 679,899 shares owned.

Recent moves by institutional investors can provide insights into their evolving perspectives on Daré Bioscience, Inc. (DARE). For instance:

• Vanguard Group Inc.: Increased its holdings by 3.7% in Q3 2023.
• BlackRock Fund Advisors: Increased its holdings by 9.8% in Q3 2023.
• State Street Global Advisors, Inc.: Decreased its holdings by 5.2% in Q3 2023.

These transactions suggest a mixed sentiment among institutional investors, with some increasing their stakes and others reducing them. Such activity can reflect differing opinions on the company's short-term and long-term prospects.

Here is a summary of significant institutional ownership and recent changes in their positions:

Understanding the composition and activities of Daré Bioscience, Inc. (DARE)'s investor base is crucial for assessing the company's market position and potential future performance. Monitoring these investors' moves and understanding their motivations can provide valuable insights for current and prospective shareholders.

To gain more insight into the values that drive Daré Bioscience, Inc. (DARE), explore: Mission Statement, Vision, & Core Values of Daré Bioscience, Inc. (DARE).

Daré Bioscience, Inc. (DARE) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions to key ownership changes is crucial for gauging the potential future trajectory of Daré Bioscience, Inc. (DARE). Shifts in major shareholdings can signal significant confidence or concern, influencing the stock's performance and overall market perception. Examining analyst perspectives further enriches this understanding, providing insights into how these investor dynamics might affect the company's strategic direction and financial health.

Recent market reactions to changes in ownership or large investor moves can significantly impact Daré Bioscience, Inc. (DARE)'s stock. For instance, a substantial purchase by a prominent institutional investor might drive the stock price up, reflecting increased confidence in the company's prospects. Conversely, a large sell-off could lead to a price decline, signaling potential concerns about future performance. Monitoring these movements helps in understanding the immediate market sentiment surrounding Daré Bioscience, Inc. (DARE).

Analyst perspectives play a vital role in interpreting the impact of key investors on Daré Bioscience, Inc. (DARE)'s future. Analysts often provide insights into how major ownership changes might influence the company's strategic decisions, financial stability, and growth potential. For example, analysts might comment on whether a new major investor's expertise aligns with Daré Bioscience, Inc. (DARE)'s business goals or if a significant reduction in holdings by a large investor indicates concerns about upcoming clinical trial results. These perspectives offer a deeper understanding of the long-term implications of investor behavior.

Current investor sentiment toward Daré Bioscience, Inc. (DARE) can be categorized as positive, neutral, or negative, each carrying distinct implications. Positive sentiment typically arises from strong clinical trial results, strategic partnerships, or favorable market conditions, attracting more investors and potentially driving up the stock price. Neutral sentiment may reflect a wait-and-see approach, where investors are holding their positions pending further developments. Negative sentiment could stem from setbacks in clinical trials, increased competition, or broader market downturns, leading to potential sell-offs.

To illustrate the types of information available, consider the following (note that this is an example and not specific current data for Daré Bioscience, Inc. (DARE)):

• Positive Sentiment: Increased investment following successful Phase 2 trial results for a new drug candidate.
• Neutral Sentiment: Steady share prices despite broader market volatility, indicating stable investor confidence.
• Negative Sentiment: Stock decline after a failed Phase 3 trial, leading to decreased investor interest.

Here's an example of how recent ownership changes and market reactions might be viewed:

• A large institutional investor increases their stake by 15% after positive clinical trial data, causing a 10% jump in stock price.
• An activist investor acquires a significant position, pushing for strategic changes and causing short-term stock volatility.
• A major shareholder reduces their holdings by 20% due to portfolio rebalancing, leading to a temporary dip in stock value.

The following table provides a hypothetical overview of how analyst ratings might reflect investor impact:

For more in-depth information on the company's background, mission, and ownership structure, you can explore: Daré Bioscience, Inc. (DARE): History, Ownership, Mission, How It Works & Makes Money.